These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 28852500)

  • 1. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
    Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
    Cancer Metab; 2017; 5():6. PubMed ID: 28852500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
    Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
    Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.
    Sohn J; Liu S; Parinyanitikul N; Lee J; Hortobagyi GN; Mills GB; Ueno NT; Gonzalez-Angulo AM
    J Cancer; 2014; 5(9):745-53. PubMed ID: 25368674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
    Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
    Nakai K; Hung MC; Yamaguchi H
    Am J Cancer Res; 2016; 6(8):1609-23. PubMed ID: 27648353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer.
    Jaradat SK; Ayoub NM; Al Sharie AH; Aldaod JM
    Technol Cancer Res Treat; 2024; 23():15330338241234780. PubMed ID: 38389413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.
    Fink LS; Beatty A; Devarajan K; Peri S; Peterson JR
    Mol Cancer Ther; 2015 Jan; 14(1):298-306. PubMed ID: 25344583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.
    Simiczyjew A; Dratkiewicz E; Van Troys M; Ampe C; Styczeń I; Nowak D
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30227653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.
    Nagaria TS; Shi C; Leduc C; Hoskin V; Sikdar S; Sangrar W; Greer PA
    Oncotarget; 2017 Oct; 8(46):80804-80819. PubMed ID: 29113345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.